TruSight Cancer

TruSight Cancer

TruSight Cancer is a 94-gene and 284-SNP sequencing panel covering 297 kb of genomic content focused on predisposition to cancer.

LT Catalog ID(s):
FC-121-0202, TG-141-1002* (Content Set for up to 48 samples, 4 enrichments)
And one or more of the following TruSight Rapid enrichment kits:
FC-140-1101, TG-140-1101* (1 index, 8 samples, 8 enrichments)
FC-140-1102, TG-140-1102* (2 indices, 8 samples, 4 enrichments)
FC-140-1103, TG-140-1103* (4 indices, 16 samples, 4 enrichments)
FC-140-1104, TG-140-1104* (24 indices, 48 samples, 4 enrichments)
FC-140-1105, TG-140-1105* (24 indices, 96 samples, 8 enrichments)
FC-140-1106, TG-140-1106* (96 indices, 288 samples, 24 enrichments)

*TG-labeled consumables include features intended to help customers reduce the frequency of revalidation. They are available only under supply agreement and require customers to provide a binding forecast. Contact your account manager for more information.

Order Now Support

Please rotate your device for details

* Library prep is compatible with all Illumina instruments. Recommended instruments chosen based on typical output and analysis need for selected application.
† Based on > 20x per target.
Project Recommendations
Species Compatibility Human
Recommended Illumina Instrument* MiniSeq MiSeq NextSeq 500
Recommended Samples per run† 12 24 12 (v2 chemistry)
24 (v3 chemistry)		 96 96
Run Mode Mid Output High Output - Mid Output High Output
Max Recommended Read Length Up to 2x150 bp Up to 2x150 bp Up to 2x150 bp Up to 2x150 bp Up to 2x150 bp
Recommended Secondary Analysis
  • Local Run Manager Enrichment
  • BaseSpace BWA Enrchiment
  • BaseSpace Isaac Enrichment
  • MiSeq Reporter Enrichment Workflow
  • BWA Enrichment BaseSpace App
  • Isaac Enrichment v2 BaseSpace App
Recommended Down Stream Analysis VariantStudio
Order Now Support
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see emea.illumina.com/company/legal.html.

© 2026 Illumina, Inc. All rights reserved.